ClinicalTrials.gg
WithdrawnNCT03342079Updated Mar 11, 2025

Effectiveness of Nitrous Oxide 50% for Reducing Pain and Distress Associated with Needle-stick in Children

An interventional study of Local Anesthetics,(lidocaine 70 mg/tetracaine 70 mg topical patch; Synera) and Placebos in Local Anesthetic Efficacy, sponsored by Boston Children's Hospital. Withdrawn. Open to participants aged 3 Years to 6 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-11.

Sponsored by Boston Children's Hospital · Not applicable, Interventional, and Treatment

Why this study was withdrawn
Lack of funding
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
3 Years to 6 Years
Sex
All
01

Study summary

Venipuncture (puncturing of a vein) through the skin in order to insert a vein catheter (also know as cannula) is one of the most common needle-related medical procedures performed in children. Venipuncture is necessary for administration of sedation to facilitate motionless patient state for radiological imaging studies such as diagnostic nuclear medicine imaging or CT scan studies.

The current practice for management of needle-related pain is to use needle-less topical local anesthetic delivery systems. These delivery systems are increasingly used in children to anesthetize the skin prior to venipuncture and venous cannulae insertion. This can reduce the pain and distress associated with the needle sticks, however, many children express considerable fear, anxiety and distress during medical procedures that involve needles. Anticipatory pain and phobia associated with needle stick may render the patient uncooperative and anxious even when effective analgesia is produced by a topical local anesthetic.

Both the discomfort and associated anxiety during such an intervention can be considerably improved when inhaled nitrous oxide is used alone or in combination with local anesthetics. The administration of nitrous oxide (50% to 70%) for painful procedures is an effective and safe method of suppressing procedural pain and distress in children over the age of one year (level 3 evidence). When compared to other intravenous sedation agents, nitrous oxide 50% used for uncomplicated painful procedures is associated with markedly shorter recovery time and less respiratory side effects (level 3 evidence). When combined with local anesthetics for procedural pain and stress management, nitrous oxide 50% is more effective and has higher success rate compared to orally administered anxiolytics or local anesthetic alone (level 2 evidence). Combining nitrous oxide (50-70%) and local anesthetics is shown to be a more effective procedural sedation than local anesthetics alone (level 1 evidence).

The efficacy and safety of inhaled 50-70% nitrous oxide for relief of mild-to-moderate anxiety and pain of venipuncture in children just prior to induction of anesthesia have been investigated in randomized controlled trials by anesthesiologists; physician who are skilled and competent in providing optimal sedation in the operating room setting. The major benefit of administration of a fixed low concentration of 50% nitrous oxide for procedural sedation is that it achieves pain relief while retaining verbal contact with the patient. The efficacy, safety and tolerability of administration of low fixed concentration 50% nitrous oxide using a nitrous oxide mask delivery system for control of mild-to-moderate procedural sedation during performance of needle-related pain (i.e., venipuncture) in children has not been investigated in a blinded randomized controlled trials outside the operating room setting when provided by skilled and competent non-anesthesia trained personnel.

In view of safety of low concentration (50%) of nitrous oxide due to preservation of the patent airway, lack of respiratory depression and rapid recovery, investigators propose this preliminary study to validate the hypothesis that nurse-administered premixed inhaled nitrous oxide and oxygen at a fixed 50:50% concentration with or without a topical anesthetic can provide safe and effective pain relief and reduce behavioral distress in preschool children during routine placement of intravenous cannulation prior to administration of intravenous sedation for nuclear medicine studies and CT imaging studies.

To test this hypothesis, investigators propose performing a prospective, double blind control trial in 105 children undergoing nuclear medicine studies or CT imaging, randomized into three groups;

  1. the treatment groups will receive either nitrous oxide and a placebo topical anesthetic patch or
  2. nitrous oxide and a topical anesthetic patch (Synera) and
  3. the placebo group will receive oxygen mask and a topical anesthetic patch (Synera).

The topical anesthetic patch or placebo patch will be applied for 20 minutes prior to the scheduled insertion of intravenous cannula. The use of a topical local anesthetic such as the Synera patch is a standard of care for placement of intravenous cannula at Children's Hospital Boston.

Assessments to estimate the effectiveness of nitrous oxide with and without the use of topical anesthesia Synera patch will include;

  1. Assessment of child's pain and observer report of pain control.
  2. Child's anxiety before and during the procedure.
  3. Tolerability of the mask delivery system of a fixed concentration of 50% nitrous oxide outside the operating room.
  4. Accuracy of nitrous oxide delivery dose by measuring the end-tidal concentration of nitrous oxide.
  5. Adverse events related to use of nitrous oxide alone or in combination with a topical analgesic.
Read the detailed description

This study was never conducted due to lack of funding

02

Conditions studied

  • Local Anesthetic Efficacy
03

In context

Lead sponsor

Boston Children's Hospital is the lead sponsor of 608 studies on the registry; 147 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Children ages 3 to 6 years of age who require diagnostic CT or nuclear medicine studies under conscious sedation

      • Guardians give consent and the child gives assent when appropriate
      • Both genders
      • All racial and ethnic groups
      • English and other languages speaking and reading children and guardians (for consent/assent purposes)

Exclusion criteria

Exclusion Criteria:

  • Age less than 3 or older than 6 years

    • Patients who had a history of adverse events with facemask; mask phobia
    • If parents/patients refuse to participate in the study
    • Fasting less than 2h for clear liquids, 4h breast milk, 6h formula and fortified breast milk for under 1 yr and 8h for over 1yr, 8h for non-human milk and solid food.
    • Impairment of cognition/neurologic, hepatic, renal, cardiovascular, endocrine, metabolic, and/or coagulation function.
    • A history of any diagnosis of psychiatric disorders as reported by parents/guardians
    • A history of chronic pain and/or use of chronic (daily around the clock) opioids, other analgesics or sedatives/hypnotics
    • Intake of prescription medications or over-the-counter medications known to affect pain perception such as narcotics, non-steroidal anti-inflammatory agents, stimulants, hypnotics, sedatives, etc. within 8 hours of planned surgical procedure
    • Vitamin B12 \& folate deficiency
    • Immune suppression (e.g., postoperative organ transplant, chemotherapy, neutropenia, any condition suppresses immunity or bone marrow)
    • Abnormal homocysteine metabolism
    • Lung cyst, bowel obstruction, middle ear disease, pneumothorax, head injury, active gastro-esophageal reflux, history of delayed gastric emptying and vomiting, upper airway obstruction, airway infection, active wheezing from asthma, and apnea
    • Significant impairments: pulmonary hypertensions, cardiomyopathy, hypovolemia, meningitis, space occupying lesions of the brain e.g. tumors, sepsis, severe liver diseases (e.g., biliary atresia, liver failure)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Group 1

    local anesthetic (lidocaine 70 mg/tetracaine 70 mg topical patch; Synera) + placebo

    Drug: Local Anesthetics,(lidocaine 70 mg/tetracaine 70 mg topical patch; Synera) · Drug: Placebos

  • Experimental
    Group 2

    local anesthetic (lidocaine 70 mg/tetracaine 70 mg topical patch; Synera) + nitrous oxide

    Drug: Local Anesthetics,(lidocaine 70 mg/tetracaine 70 mg topical patch; Synera)

  • Placebo comparator
    Group 3

    Placebo + nitrous oxide

    Drug: Placebos

Interventions

  • DrugLocal Anesthetics,(lidocaine 70 mg/tetracaine 70 mg topical patch; Synera)

    Drug page: Lidocaine

    topical anesthetic (lidocaine 70 mg/tetracaine 70 mg topical patch; Synera)

    Also known as: Synera

  • DrugPlacebos

    placebo topical anesthetic

    Also known as: Synera patch without local anesthetics

06

What researchers measure

Primary outcomes

  1. Analgesia measured using the Observational Visual Analog Pain Assessment Scale (0= no pain and 10= unimaginable severe pain)

    decrease pain during venous blood drawing

    Time frame: During venipuncture procedure

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2017
First posted
Nov 14, 2017
Start
Mar 2014
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Last update
Mar 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03342079
Collaborators
Linde AG
Responsible party
Navil Sethna (Anesthesiologist, Boston Children's Hospital) — Principal investigator
First posted
Nov 14, 2017
Start date
Mar 2014
Primary completion
Dec 2014
Completion
Dec 2014
Last update
Mar 11, 2025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion